Skip to main content
Premium Trial:

Request an Annual Quote

Bio-Rad Receives Notice From NYSE for Late Filing of Annual Report

NEW YORK (GenomeWeb) – Bio-Rad Laboratories said today that it has received an expected notice from the New York Stock Exchange about not complying with its listing requirements because it is late filing its annual report for fiscal year 2017 on Form 10-K with the US Securities and Exchange Commission.

The previously disclosed reason for the delay is that Bio-Rad's independent registered public accounting firm needs more time to complete its audit if the company's 2017 financial statements. This includes assessing the effectiveness of Bio-Rad's internal control over financial reporting related to its conversion to a new enterprise resource planning (ERP) system and business structure for a large portion of its European operations.

Bio-Rad said it intends to file its 2017 Form 10-K as soon as possible after the audit is complete.  

Under NYSE rules, Bio-Rad has six months from the due date to file the 2017 Form 10-K and will regain compliance with the listing standards when it does.

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people over 65 or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.